reports
Sanofi: 1 director
A director at Sanofi bought 500 shares at 82.700EUR and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing C...
- Bruno Cavalier
- Jerôme Bodin
- Thijs Berkelder
- Christophe-Raphaël Ganet
- Bruno Cavalier
- Jerôme Bodin
- Thijs Berkelder
- Christophe-Raphaël Ganet
Communiqué de presse : Mise en ligne du document «Q2 2025 Aide mémoire...
Communiqué de presse : Mise en ligne du document «Q2 2025 Aide mémoire » Mise en ligne du document «Q2 2025 Aide mémoire » Paris, France, le 30 juin 2025. Sanofi annonce la mise en ligne sur l'espace Investisseurs du site internet de la société, d'un document intitulé « Q2 2025 Aide mémoire ». Comme chaque trimestre, ce document vise à assister la communauté financière dans la modélisation des résultats trimestriels de la société. Ce document contient un rappel de divers éléments non récurrents, l’effet des variations monétaires et le nombre d’actions. Les résultats du premier tri...
Press release: Availability of the Q2 2025 Aide mémoire
Press release: Availability of the Q2 2025 Aide mémoire Availability of the Q2 2025 Aide mémoire Paris, France – June 30, 2025. Sanofi announced today that its Q2 2025 Aide mémoire is available on the "Investors" page of the company's website: As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various non-comparable items, as well as the foreign currency impact and share count. Sanofi's second quarter 2025 results will be published on July 31, 2025. About Sanofi...
Press Release: Riliprubart granted orphan drug designation in Japan fo...
Press Release: Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy Two phase 3 studies are currently underway testing riliprubart in people with CIDP as a potential first-in-class treatmentJapanese Ministry of Health, Labour and Welfare decision adds to similar designations in the US and Europe, underscoring global regulatory recognition of the potential for riliprupart to address significant unmet medical needs for people living...
Communiqué de presse : Le riliprubart obtient la désignation de médica...
Communiqué de presse : Le riliprubart obtient la désignation de médicament orphelin au Japon pour la polyneuropathie inflammatoire démyélinisante chronique Le riliprubart obtient la désignation de médicament orphelin au Japon pour la polyneuropathie inflammatoire démyélinisante chronique Deux études de phase 3 sont actuellement en cours pour tester le riliprubart chez les personnes atteintes de PIDC comme traitement potentiel meilleur de sa catégorieLa décision du ministère de la Santé, du Travail et des Affaires sociales du Japon s’ajoute aux désignations similaires aux États-Unis et en ...
Eurofins Scientific S.E: 1 director
A director at Eurofins Scientific S.E bought 7,432 shares at 59.572EUR and the significance rating of the trade was 63/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...
- Carole Braudeau
BMW BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT
RNO RENAULT SA
DAI DAIMLER AG
KORI KORIAN SA
GLE SOCIETE GENERALE S.A. CLASS A
KER KERING SA
VOW3 VOLKSWAGEN AG PREF
CCL CARNIVAL PLC
REC RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A.
WBD WEBUILD S.P.A.
WLN WORLDLINE SA
RACE FERRARI NV
SAB BANCO DE SABADELL SA
STLA STELLANTIS N.V.
OVH OVH GROUPE
- Carole Braudeau
BMW BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT
RNO RENAULT SA
DAI DAIMLER AG
KORI KORIAN SA
GLE SOCIETE GENERALE S.A. CLASS A
KER KERING SA
VOW3 VOLKSWAGEN AG PREF
CCL CARNIVAL PLC
REC RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A.
WBD WEBUILD S.P.A.
WLN WORLDLINE SA
RACE FERRARI NV
SAB BANCO DE SABADELL SA
STLA STELLANTIS N.V.
OVH OVH GROUPE
- Klaus Ringel
- Klaus Ringel
- Delphine Chauvin
Clariane : Clariane a fait un retour éclair sur les marchés obligatair...
Hier, profitant d’une fenêtre d’apaisement sur les marchés, suite à l’annonce d’un cessez-le-feu entre l’Iran et Israël, Clariane a lancé le placement d’une nouvelle obligation à échéance juin 2030 (5 ans). Le price-talk a débuté à « 8.25% area » et les titres ont été placés dans la journée, avec, au final, un pricing resserré à 7.875% (ms+565bp) et un relèvement de la taille à 400 m EUR (vs. 300 m EUR prévu au départ). Plus de 1.15 md EUR d’ordres auraient été apportés au book. L’opération est ...
- Delphine Chauvin
Clariane : Clariane stages whirlwind bond market comeback
Yesterday, capitalising on a window of calm on the markets following the announcement of a ceasefire between Iran and Israel, Clariane launched the placement of a new bond maturing in June 2030 (five years). The price-talk began in the "8.25% area" and the notes were issued during the day, with a final pricing of 7.875% (MS+565bp) and an increase in the size to € 400m (vs. € 300m initially forecast). More than € 1.15bn worth of orders were added to the book The issuance is "non-rated'", with a p...
- Christophe-Raphaël Ganet
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.